Strenghtening collaboration with Serbia

- IPA4 Project expected outcomes

Frédéric Denecker, Programme Management Officer

Reitox and International Cooperation Unit

Belgrade, 22 November 2012

2emcdda.europa.eu

Building on past and present, towards future

IPA 3 project - experience and outcomes in Serbia

IPA 4 project - specific objectives and expected outcomes

Twinning project - streamlining of activities and avoiding overlap

3emcdda.europa.eu

Information available through IPA cooperation

Drug situation:

First National report

Country overview

ESPAD survey

Data collection tools:

Information map

National Action Plan for Drug information system (NAPDIS)

Translated EPI Key Indicators protocols

4emcdda.europa.eu

Activites under IPA 3 in Serbia

Successful establishment of a working group

for drafting fist national report & documents

Specific support from Cypriot Reitox NFP

Increased visibility of the information from

Serbia

Availability of reference documents in national

language

(EMCDDA protocols on KI, guidelines on harm

reduction,…)

5emcdda.europa.eu

Activites under IPA 3 in Serbia

R

egional Reitox Academies on:

Drug-related death indicator (Skopje)

National reporting (Lisbon)

Early Warning system (Tirana)

Exchanges with EU experts at meetings and study

visit to Cyprus

6emcdda.europa.eu

EMCDDA-IPA 4 project

January 2012 – November 2014

Overall budget: € 900.000

The project is financed through the Instrument of Pre-accession Assistance (IPA) of DG Enlargement of the European Commission

Implemented an coordinated by the EMCDDA, in close collaboration with Reitox Focal Points and EU experts

7emcdda.europa.eu

Areas for future collaboration: Epidemiology

GPS (incl. school surveys)- possible methodological support for pilot survey- possible co-financing for data collection- continuous support for ESPAD, dissemination of results

PDU- methodological support for further development of PDU (so far only IDU estimation is available)

TDI- Increase participation of treatment centres to data collection and sharing protocol

DRID- methodological support for data collection and for data analysis

DRD- Support to involved institutions to improve data collection

8emcdda.europa.eu

Areas for future collaboration:Policy & interventions- best practices

Reitox academy in October “Monitoring and evaluation of national drug strategies” (Riga)

Interest on methods for estimates of Public expenditures

PreventionDissemination of information on standards for prevention-focus on indicated and selective

Harm reductionSupport for monitoring interventions including in prisons; dissemination of the joint EMCDDA-ECDC guidelines on prevention of infections

9emcdda.europa.eu

Areas for future collaboration:Supply reduction and new trends

New substances appearing at EU level

Domestic cultivation reported in all European countries

New indicators being negotiated at EU level

10emcdda.europa.eu

Areas for future collaboration:Building an integrated system

Ad-hoc support to National Focal Building

Update of the information map

Update of the NAPDIS (in view of its official adoption ?)

Coordination mechanisms for exchange of data

Roadmap for EMCDDA accession

11emcdda.europa.eu

IPA 4: common activities to all beneficiaries

1. Mandatory outputs to be improved with support of EMCDDA feedback: country overview, national report, information map, NAPDIS and EMCDDA Roadmap.

2. Contribution to a regional publication at the end of project 3. Participation at:

- Extended Reitox Week (May)- Selected Epidemiological key indicators meetings- Early Warning System experts meeting- Reitox Academy Training activities:

- EU affairs (Jan 2013)- National data reporting (Feb-March 2013)- Spring University School (April 2013)

- IPA4 project coordination meetings

12emcdda.europa.eu

IPA 4: Milestones 2012-2013

1-12 12-12

Fev Mar Abr Mai Jun Jul Ago Set Out Nov Dez

11/15/2012

EMCDDA- IPA 4- Milestones 2012

Outputs:

Ago - AgoBreak

Jan - MarNC nomination + prep nat meetings

JunNational workplans

JunGPS KI26-27

DezCO ready

OutPDU KI25-26Out

DRID KI11-12

NovDRD KI12-13

Mar - MaiNational meetings

SetTDI KI20-21

MaiEWS24-25

MaiRTX week + HFPs

29-1

OutDeadline NRFor HR + TR

DezUpdating CO

IPA beneficiaries

NovEMCDDA AR

SetDeadline Fonte

for HR + TR

13emcdda.europa.eu

IPA 4: immediate next steps

Discussion on joint activities and priorities for cooperation

Endorsement of the work programme at national level

Re-activation national working group/-s

Streamlining of activities with Twinning project

14emcdda.europa.eu

Resources always available

Annual reportDrugnet Europe

Country overviews

Statistical bulletin

15emcdda.europa.eu

Looking at the bigger picture

Main conclusions from 2012 EMCDDA AR:

Europe has a more stable drug use situation (e.g. further signs of falling use and status of cocaine)

Complex stimulant market and plethora of powders and pills (i.e. fast moving, volatile market - difficult to control), incl. new trafficking routes and record number of online shops selling ‘legal highs’

Important to improve understanding of health and social impact of emerging trends and to develop measures to reduce demand

Investment in treatment and harm reduction has proved successful but still room for progress in prevention, social reintegration, prisons

Recession - impact on Europe’s drug problems and responses?

16emcdda.europa.eu

Thank you for your attention!